zmz tirzepatide FDA Grants a New Indication for Obesity Management Ito na nga ichcheck-out ko
Description
The FDA has restricted compounded tirzepatide now that manufacturer supply has stabilized
The SURMOUNT-5 trial answered it directly, putting tirzepatide head-to-head against semaglutide over 72 weeks
No Decision on the Merits (Yet) The ruling didnt weigh in on the legality or marketing of compounded tirzepatide
No third-party testing documentation
MASH affects around 14.9 million adults in the U.S., or roughly 6% of the population, and its prevalence is on the rise
